Showing results (131-140 of 286) with videos related to
Sort By:
Pageof 29
The Oncologist|July 9, 2025
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumorsJohn D Powderly, Martin E Gutierrez, Ani S Balmanoukian, et al.Transplantation and Cellular Therapy|March 15, 2025
Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal ProductsJustin J Lievense, Cynthia Nijenhuis, Inge Jedema, et al.Japanese Journal of Clinical Oncology|February 22, 2020
Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival dataChristopher J D Wallis, Keith Lawson, Mohit Butaney, et al.Journal of Drugs in Dermatology : JDD|February 11, 2014
Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week resultsBrian Berman, Gary Goldenberg, C William Hanke, et al.Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.Cancer Immunity|July 9, 2013
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaJeffrey Weber, Omid Hamid, Asim Amin, et al.Journal for Immunotherapy of Cancer|February 29, 2024
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapyAllison Betof Warner, Omid Hamid, Krishna Komanduri, et al.Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.Journal of the American Academy of Dermatology|January 20, 2020
Quantitative metastatic lymph node burden and survival in Merkel cell carcinomaAnthony T Nguyen, Michael Luu, Diana J Lu, et al.Pageof 29